Cargando…
Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart
Previous studies have shown that glucagon-like peptide-1 (GLP-1) provides cardiovascular benefits independent of its role on peripheral glycemic control. However, the precise mechanism(s) by which GLP-1 treatment renders cardioprotection during myocardial ischemia remain unresolved. Here we examined...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476748/ https://www.ncbi.nlm.nih.gov/pubmed/26098939 http://dx.doi.org/10.1371/journal.pone.0130894 |
_version_ | 1782377647722987520 |
---|---|
author | Aravindhan, Karpagam Bao, Weike Harpel, Mark R. Willette, Robert N. Lepore, John J. Jucker, Beat M. |
author_facet | Aravindhan, Karpagam Bao, Weike Harpel, Mark R. Willette, Robert N. Lepore, John J. Jucker, Beat M. |
author_sort | Aravindhan, Karpagam |
collection | PubMed |
description | Previous studies have shown that glucagon-like peptide-1 (GLP-1) provides cardiovascular benefits independent of its role on peripheral glycemic control. However, the precise mechanism(s) by which GLP-1 treatment renders cardioprotection during myocardial ischemia remain unresolved. Here we examined the role for GLP-1 treatment on glucose and fatty acid metabolism in normal and ischemic rat hearts following a 30 min ischemia and 24 h reperfusion injury, and in isolated cardiomyocytes (CM). Relative carbohydrate and fat oxidation levels were measured in both normal and ischemic hearts using a 1-(13)C glucose clamp coupled with NMR-based isotopomer analysis, as well as in adult rat CMs by monitoring pH and O(2) consumption in the presence of glucose or palmitate. In normal heart, GLP-1 increased glucose uptake (↑64%, p<0.05) without affecting glycogen levels. In ischemic hearts, GLP-1 induced metabolic substrate switching by increasing the ratio of carbohydrate versus fat oxidation (↑14%, p<0.01) in the LV area not at risk, without affecting cAMP levels. Interestingly, no substrate switching occurred in the LV area at risk, despite an increase in cAMP (↑106%, p<0.05) and lactate (↑121%, p<0.01) levels. Furthermore, in isolated CMs GLP-1 treatment increased glucose utilization (↑14%, p<0.05) and decreased fatty acid oxidation (↓15%, p<0.05) consistent with in vivo finding. Our results show that this benefit may derive from distinct and complementary roles of GLP-1 treatment on metabolism in myocardial sub-regions in response to this injury. In particular, a switch to anaerobic glycolysis in the ischemic area provides a compensatory substrate switch to overcome the energetic deficit in this region in the face of reduced tissue oxygenation, whereas a switch to more energetically favorable carbohydrate oxidation in more highly oxygenated remote regions supports maintaining cardiac contractility in a complementary manner. |
format | Online Article Text |
id | pubmed-4476748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-44767482015-06-25 Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart Aravindhan, Karpagam Bao, Weike Harpel, Mark R. Willette, Robert N. Lepore, John J. Jucker, Beat M. PLoS One Research Article Previous studies have shown that glucagon-like peptide-1 (GLP-1) provides cardiovascular benefits independent of its role on peripheral glycemic control. However, the precise mechanism(s) by which GLP-1 treatment renders cardioprotection during myocardial ischemia remain unresolved. Here we examined the role for GLP-1 treatment on glucose and fatty acid metabolism in normal and ischemic rat hearts following a 30 min ischemia and 24 h reperfusion injury, and in isolated cardiomyocytes (CM). Relative carbohydrate and fat oxidation levels were measured in both normal and ischemic hearts using a 1-(13)C glucose clamp coupled with NMR-based isotopomer analysis, as well as in adult rat CMs by monitoring pH and O(2) consumption in the presence of glucose or palmitate. In normal heart, GLP-1 increased glucose uptake (↑64%, p<0.05) without affecting glycogen levels. In ischemic hearts, GLP-1 induced metabolic substrate switching by increasing the ratio of carbohydrate versus fat oxidation (↑14%, p<0.01) in the LV area not at risk, without affecting cAMP levels. Interestingly, no substrate switching occurred in the LV area at risk, despite an increase in cAMP (↑106%, p<0.05) and lactate (↑121%, p<0.01) levels. Furthermore, in isolated CMs GLP-1 treatment increased glucose utilization (↑14%, p<0.05) and decreased fatty acid oxidation (↓15%, p<0.05) consistent with in vivo finding. Our results show that this benefit may derive from distinct and complementary roles of GLP-1 treatment on metabolism in myocardial sub-regions in response to this injury. In particular, a switch to anaerobic glycolysis in the ischemic area provides a compensatory substrate switch to overcome the energetic deficit in this region in the face of reduced tissue oxygenation, whereas a switch to more energetically favorable carbohydrate oxidation in more highly oxygenated remote regions supports maintaining cardiac contractility in a complementary manner. Public Library of Science 2015-06-22 /pmc/articles/PMC4476748/ /pubmed/26098939 http://dx.doi.org/10.1371/journal.pone.0130894 Text en © 2015 Aravindhan et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Aravindhan, Karpagam Bao, Weike Harpel, Mark R. Willette, Robert N. Lepore, John J. Jucker, Beat M. Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart |
title | Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart |
title_full | Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart |
title_fullStr | Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart |
title_full_unstemmed | Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart |
title_short | Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart |
title_sort | cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476748/ https://www.ncbi.nlm.nih.gov/pubmed/26098939 http://dx.doi.org/10.1371/journal.pone.0130894 |
work_keys_str_mv | AT aravindhankarpagam cardioprotectionresultingfromglucagonlikepeptide1administrationinvolvesshiftingmetabolicsubstrateutilizationtoincreaseenergyefficiencyintheratheart AT baoweike cardioprotectionresultingfromglucagonlikepeptide1administrationinvolvesshiftingmetabolicsubstrateutilizationtoincreaseenergyefficiencyintheratheart AT harpelmarkr cardioprotectionresultingfromglucagonlikepeptide1administrationinvolvesshiftingmetabolicsubstrateutilizationtoincreaseenergyefficiencyintheratheart AT willetterobertn cardioprotectionresultingfromglucagonlikepeptide1administrationinvolvesshiftingmetabolicsubstrateutilizationtoincreaseenergyefficiencyintheratheart AT leporejohnj cardioprotectionresultingfromglucagonlikepeptide1administrationinvolvesshiftingmetabolicsubstrateutilizationtoincreaseenergyefficiencyintheratheart AT juckerbeatm cardioprotectionresultingfromglucagonlikepeptide1administrationinvolvesshiftingmetabolicsubstrateutilizationtoincreaseenergyefficiencyintheratheart |